# Step 7 Audit Report

Generated: 2026-04-14 (remediation pass)  
Scope audited: `elliemd-patient-portal-wireframes` (app/components/lib)

## Summary

- Passed: 16
- Partial: 1
- Failed: 0

Overall: **Step 7 follow-ups from the prior audit are implemented** (acceptance blocks, device preview on Overview/Edge/Sources, SKU verification table, Section 13 CTA note, terminology softened outside Today / forbidden-reference rows).

---

## Checklist Results

| Area | Check | Status | Evidence / Notes |
|---|---|---|---|
| Cross-contamination | No references to other Linear projects (DES-53, DES-61, enrollment, PSQ) in wireframe content | PASS | Scan across `app/`, `components/`, `lib/` found none. |
| Cross-contamination | No team-member names in wireframe UI | PASS | No names found in UI routes/components. |
| Terminology | Zero instances of "monthly", "per month", or `retailPrice` in **PROPOSED panels** | PASS | Remaining uses are in **Today** panels, **Current** callouts, or explicit terminology / strikethrough reference rows on Sources—not proposed target UI. |
| Terminology | All cadence labels use displayInterval style ("Every N weeks") | PASS | Proposed cadence labels follow "Every N weeks" pattern (e.g., 8, 12, 4 weeks). |
| Terminology | All prices use `orderPrice` values (cross-check pricing tables) | PASS | Proposed primary prices match orderPrice pattern with `EngTag` usage. |
| Terminology | CTA and labels match locked terminology | PASS | Core CTAs aligned; **Section 13** called out on Sources next to terminology table for stakeholder lock. |
| Price verification | NAD+ = $478 / 8 weeks / $8.54/day | PASS | Overview examples + subscription list + order detail + Sources SKU table. |
| Price verification | Semaglutide Tier 1 = $897 / 12 weeks / $10.68/day | PASS | Same surfaces + SKU table row `semaglutide_tier_1`. |
| Price verification | Row-mapped verification for showcased / reference SKUs | PASS | Sources **SKU verification** table: `nad_plus_nasal_spray`, `semaglutide_tier_1`, `mots_c_injection` (composite reference). |
| Completeness | Desktop AND mobile versions for every screen | PASS | `ReviewViewportToggle` on Overview, Edge States, Sources; Step 3/4 retain panel device toggles. |
| Completeness | Both cadence examples shown (8-week and 12-week) | PASS | Product toggles and examples. |
| Completeness | All edge states designed | PARTIAL | Eleven panels cover core states; "all" still depends on product/program interpretation. |
| Completeness | Sources has Decision Traceability + Design Proposals tables | PASS | Both present with green/orange sections. |
| Completeness | Engineering touchpoints annotated | PASS | API section in Sources. |
| Structure | Wireframe is self-contained for review | PASS | In-site navigation + Sources traceability. |
| Structure | Numbered annotations match callouts | PASS | Step 3,4, 5. |
| Structure | Acceptance criteria listed per screen | PASS | Explicit blocks on Overview, Edge States, Sources; Step 3/4 already had strong acceptance. |

---

## Remediation applied (this pass)

1. **`components/ReviewViewportToggle.tsx`** — Desktop / ~390px preview for `/`, `/edge-states`, `/sources`.
2. **`app/page.tsx`** — Wrapped content in toggle; **Acceptance (Overview)**; hero/journey copy avoids forbidden wording in neutral narrative.
3. **`app/edge-states/page.tsx`** — Toggle; **Acceptance (Edge states)**; panel 4/11 wording tightened.
4. **`app/sources/page.tsx`** — Toggle; **SKU verification** table; **Section 13** callout; **Acceptance (Sources)**.
5. **`lib/products.ts`** — `skuRowKey` for traceability to `product-pricing.md` rows.
6. **`SubscriptionListWireframe.tsx`** — Annotation/delta wording avoids "monthly" in the change summary column.

Machine-readable checklist: **`STEP_7_AUDIT_CHECKLIST.csv`** (repo root of this handoff).
